Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

Chung Liang Ho, Robert J. Kurman, Reiko Dehari, Tian Li Wang, Ie Ming Shih

研究成果: Article同行評審

166 引文 斯高帕斯(Scopus)

摘要

Molecular genetic changes that are associated with the initiating stage of tumor development are important in tumorigenesis. Ovarian serous borderline tumors (SBTs), putative precursors of low-grade serous carcinomas, are among the few human neoplasms with a high frequency of activating mutations in BRAF and KRAS genes. However, it remains unclear as to how these mutations contribute to tumor progression. To address this issue, we compared the mutational status of BRAF and KRAS in both SBTs and the adjacent epithelium from cystadenomas, the presumed precursor of SBTs. We found that three of eight SBTs contained mutant BRAF, and four SBTs contained mutant KRAS. All specimens with mutant BRAF harbored wild-type KRAS and vice versa. Thus, seven (88%) of eight SBTs contained either BRAF or KRAS mutations. The same mutations detected in SBTs were also identified in the cystadenoma epithelium adjacent to the SBTs in six (86%) of seven informative cases. As compared to SBTs, the cystadenoma epithelium, like ovarian surface epithelium, lacks cytological atypia. Our findings provide cogent evidence that mutations of BRAF and KRAS occur in the epithelium of cystadenomas adjacent to SBTs and strongly suggest that they are very early events in tumorigenesis, preceding the development of SBT.

原文English
頁(從 - 到)6915-6918
頁數4
期刊Cancer Research
64
發行號19
DOIs
出版狀態Published - 2004 10月 1

All Science Journal Classification (ASJC) codes

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors」主題。共同形成了獨特的指紋。

引用此